An AI-Assisted Agentic System for Ultrasound Scanning and Diagnosis of Ovarian Lesions
New Strategy of Knowledge-Enhanced Large Model for Ultrasound Scanning and Diagnosis of Ovarian Masses
Investigators developed an interactive agentic system designed to guide newly qualified sonographers in ovarian lesion scanning and improve their scanning quality and diagnostic performance toward expert-level standards. Our agentic system is capable of capturing key features including the max-diameter plane of ovarian lesions from dynamic ultrasound videos, translating these findings into standardized International Ovarian Tumor Analysis (IOTA) descriptors, and providing multi-turn guidance for subsequent scanning, and ultimately generating an AI-assisted diagnostic assessment based on embedded expert knowledge.
In this multicenter study, participants are asked to undergo gynecological ultrasonography performed by sonographers with less than 3 years of experience with or without AI assistance. Our researchers will compare the performance of operators working with AI against that of operators working without AI, as well as against the performance of expert sonographers, to see whether AI assistance enhances the proficiency of less experienced operators and help them approach the scanning quality and diagnostic accuracy of expert sonographers in real-world clinical scenarios.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This multicenter, prospective study will be conducted at tertiary cancer centers and primary healthcare institutions across China. Participants will be recruited from gynecological ultrasound clinics of each site.
Each participant will undergo gynecological ultrasonography under both AI-assisted and unassisted conditions according to their group allocation. Following completion of the study examinations, expert sonographers with more than 10 years of experience, blinded to the scanning and diagnostic results of the junior sonographers, will independently perform a repeat gynecological ultrasound examination of each participant. Based solely on their independent examination, they will issue the final clinical report for each participant. The expert assessments will serve as one reference standard for evaluating scanning completeness, feature interpretation accuracy and diagnostic agreement. Histopathological findings, when available, or clinical follow-up for conservatively managed lesions will serve as the reference standard for evaluating diagnostic accuracy.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Jiale Qin, Prof., Professor
- Número de telefone: +86 0571-89998869
- E-mail: qinjiale@zju.edu.cn
Estude backup de contato
- Nome: Ruixia Dai, Ph.D. student
- E-mail: 12418399@zju.edu.cn
Locais de estudo
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- Women's Hospital School Of Medicine Zhejiang University
-
Contato:
- Jiale Qin, Prof., Professor
- Número de telefone: +86 0571-89998869
- E-mail: qinjiale@zju.edu.cn
-
Contato:
- Ruixia Dai, Ph.D. student
- E-mail: 12418399@zju.edu.cn
-
Shaoxing, Zhejiang, China, 311800
- Shaoxing Maternity and Child Health Care Hospital
-
Contato:
- Hua Yuan, Chief physician in ultrasound
- Número de telefone: +86 0575-88211352
- E-mail: yh0464@163.com
-
Contato:
- Xuezhen Lou, Attending physician
- E-mail: 505571621@qq.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Female aged 18-75 years
- With suspected ovarian masses identified clinically or by previous imaging examination
- Eligible for and able to undergo transvaginal or transabdominal ultrasonography
- Agree to provide written informed consent before enrollment
Exclusion Criteria:
- No ovarian mass identified on ultrasound examination
- Previous bilateral oophorectomy
- Previous surgery or chemotherapy for ovarian cancer
- Previous treatment for other malignant tumors
- Presence of any psychiatric or psychological disorders that may prevent completion of the study procedures or follow-up
- Concurrent participation in other clinical trials that may interfere with the outcomes of this study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Arm A: experimental sequence of non-AI exertion followed by AI-assisted exertion
The goal is to test the within-operator effect associated with AI assistance by comparing the performance of the same junior sonographer before and after AI guidance, and to compare the performance of both AI-assisted and unaided junior sonographers with that of the standalone AI model.
|
Participants first undergo ultrasound scanning and diagnosis by a junior sonographer without AI assistance, followed by ultrasound scanning by the same sonographer with AI assistance.
|
|
Arm B: experimental sequence of AI-assisted exertion followed by non-AI exertion
The goal is to test the clinical utility of AI with minimized potential carry-over effects and recall bias caused by repeated examinations on the same patient, by comparing the performance of one junior sonographer with AI-assisted, with that of independent unaided junior sonographers, and by comparing the performance of both AI-assisted junior sonographers and another unaided ones with that of the standalone AI model.
|
Participants first undergo ultrasound scanning and diagnosis by a junior sonographer with AI assistance, followed by ultrasound scanning by another junior sonographer without AI assistance.
The two junior sonographers are blinded to each other's scanning and assessment results.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Completeness of ultrasound feature acquisition
Prazo: Up to 7 days from completion of the study
|
The completeness of ultrasound feature acquisition will be assessed with reference to national authoritative quality-control standards.
After each examination, all stored ultrasound images and videos will be labeled according to their intended purpose.
A feature will be considered adequately acquired when at least one stored image or video provides sufficient visual evidence for assessment of that feature.
The proportion of required features successfully acquired will be calculated.
The proportion of redundant stored images will also be recorded as an additional indicator of acquisition quality.
|
Up to 7 days from completion of the study
|
|
Accuracy of interpretation of individual ultrasound features
Prazo: Up to 7 days from completion of the study
|
The accuracy of interpretation of ultrasound features will be assessed by comparing the assessments made by junior sonographers under AI-assisted and unassisted conditions with the findings independently acquired and interpreted by expert sonographers during a separate repeat ultrasound examination.
The accuracy rate for each feature will be calculated.
|
Up to 7 days from completion of the study
|
|
Agreement between junior and expert sonographers in ultrasound diagnosis
Prazo: Up to 7 days from completion of the study
|
Agreement between junior and expert sonographers will be assessed for the final diagnosis of ovarian lesions.
The assessments made by junior sonographers under AI-assisted and unassisted conditions will be compared with the corresponding diagnoses independently obtained by expert sonographers during a separate repeat ultrasound examination, which will then be quantified using appropriate agreement statistics.
|
Up to 7 days from completion of the study
|
|
Diagnostic accuracy of ovarian tumors
Prazo: Within 3 months after the ultrasonography examination
|
Diagnostic accuracy will be assessed against histopathological diagnosis as the golden reference standard.
This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
|
Within 3 months after the ultrasonography examination
|
|
Diagnostic performance of ovarian tumors
Prazo: Within 3 months after the ultrasonography examination
|
Area under curve will be assessed against histopathological diagnosis as the golden reference standard.
This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
|
Within 3 months after the ultrasonography examination
|
|
Diagnostic performance of ovarian tumors
Prazo: Within 3 months after the ultrasonography examination
|
Diagnostic sensitivity and specificity will be assessed against histopathological diagnosis as the golden reference standard.
This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
|
Within 3 months after the ultrasonography examination
|
|
Diagnostic performance of ovarian tumors
Prazo: Within 3 months after the ultrasonography examination
|
Diagnostic F1-score will be assessed against histopathological diagnosis as the golden reference standard.
This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
|
Within 3 months after the ultrasonography examination
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Confidence in ultrasound feature acquisition and diagnosis
Prazo: Up to 7 days from completion of the study
|
Sonographers' confidence in the completeness and adequacy of feature acquisition and in their final diagnostic assessment will be evaluated using a predefined rating scale as follows: 5 = very confident, 4 = confident, 3 = uncertain, 2 = less confident, and 1 = not confident at al.
|
Up to 7 days from completion of the study
|
Colaboradores e Investigadores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- IRB-20250490-R
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .